Is the next great leap in human machine integration to come not from smartphones or AI chatbots, but from a coin-sized chip implanted in the brain? Elon Musk’s Neuralink is hurtling toward that vision, announcing plans to start high-volume production of its BCI devices and to transition to fully automated surgical implantation by 2026.
The implant, called “Telepathy,” is designed for people with severe paralysis, letting them use their minds to control computers, smartphones, and other digital tools. Neura link’s first recipient in humans has already shown real-world applications-playing video games, browsing the internet, posting on social media, and moving a cursor on a laptop-with no physical input devices. Demonstrations are a tangible transition from laboratory prototypes to functional assistive technology.
The path that Neuralink has taken to arrive at this point has been full of technical and regulatory complexity. First rejected by the U.S. Food and Drug Administration in 2022 because of safety concerns that ranged from issues of the lithium battery enclosed within the implant to other risks associated with wire migration inside the brain and safe extraction procedures, it recently resolved those issues and was cleared in 2024 to start human trials. The FDA classified the implant as a high-risk Class III medical device; rigorous testing would be required not just for the implant itself but also for the surgical robot and decoding software.
Featuring a precision sewing machine-like design, the surgical robot is fitted with cameras, sensors, and a needle finer than human hair to insert the ultra-fine electrode threads into targeted areas of the brain. Neura link hopes to make the process “almost fully automated,” a development which should reduce the variability between procedures and accelerate surgery times while enabling scaling to thousands of patients a year. By 2031, the company believes it will be operating more than 20,000 annual brain surgeries across five large U.S. clinical centers.
The underlying technology, however, utilizes decades of research into BCI but brings together engineering advances in many different areas. In associated work, for instance, scientists have demonstrated the possibility of speech decoding from neural activity with a mean accuracy of over 97% after only scant calibration, using arrays of microelectrodes implanted in the cerebral cortex and artificial neural networks that decode in real time. Other studies have employed cortical implants in conjunction with stimulation of the spinal cord to accomplish at least partial restoration of motor function, drawing on adaptive algorithms such as the REW-MSLM to read electrocorticography signals and elicit appropriate muscle contraction patterns.
Without using any wires or requiring batteries with physical connectors to recharge, Neuralink’s Telepathy device contains custom chips and electronics that capture the neural activity under the implant. The captured activity in the implant is transmitted out to the external devices for decoding, and the decoding software translates these raw neural signals into actionable commands to move the cursor, type text, or control connected smart devices. The company’s PRIME Study has already enrolled participants with either cervical spinal cord injury or ALS. At The Miami Project to Cure Paralysis, surgeons implanted Telepathy in a paralyzed U.S. military veteran who now controls his phone and computer using only his thoughts.
“They’re giving me my spark back…my drive back. They’ve given me my purpose back,” said the recipient, underscoring the life-changing potential of this technology. Beyond Telepathy, Neura link is working on a device that aims at restoring vision through direct stimulation of the visual cortex-called “Blindsight.” If successful, this could open up applications in sensory restoration along with motor control and further broaden the scope of neuro prosthetics. Musk has framed the technology’s first use case as one of empowerment of those who have lost the function of their limbs, but he also suggests broader ambitions-augmenting human cognition and eventually combining biological intelligence with artificial intelligence.
While these latter visions are necessarily speculative, the technical milestones reached to date-wireless high-fidelity neural recording, robotic micro-surgery, and real-time translation of thought-to-action-are laying the groundwork for a completely new category of medical and computational interface. With 12 patients already using Neuralink implants around the world and having attained a valuation of $9 billion after funding round involvement by $650 million, the company seems to be setting the pace for neurotechnology commercialization. The next challenge lies in scaling production, ensuring long-term safety, and proving consistent performance across thousands of users-a task that will test not only engineering precision but also regulatory, ethical, and societal readiness for brain-linked computing.
